Literature DB >> 27794578

Aberrant Splicing in Cancer: Mediators of Malignant Progression through an Imperfect Splice Program Shift.

Felipe Andrés Cordero Luz1, Paula Cristina Brígido, Alberto Silva Moraes, Marcelo José Barbosa Silva.   

Abstract

Although the efforts to understand the genetic basis of cancer allowed advances in diagnosis and therapy, little is known about other molecular bases. Splicing is a key event in gene expression, controlling the excision of introns decoded inside genes and being responsible for 80% of the proteome amplification through events of alternative splicing. Growing data from the last decade point to deregulation of splicing events as crucial in carcinogenesis and tumor progression. Several alterations in splicing events were observed in cancer, caused by either missexpression of or detrimental mutations in some splicing factors, and appear to be critical in carcinogenesis and key events during tumor progression. Notwithstanding, it is difficult to determine whether it is a cause or consequence of cancer and/or tumorigenesis. Most reviews focus on the generated isoforms of deregulated splicing pattern, while others mainly summarize deregulated splicing factors observed in cancer. In this review, events associated with carcinogenesis and tumor progression mainly, and epithelial-to-mesenchymal transition, which is also implicated in alternative splicing regulation, will be progressively discussed in the light of a new perspective, suggesting that splicing deregulation mediates cell reprogramming in tumor progression by an imperfect shift of the splice program.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27794578     DOI: 10.1159/000450650

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  7 in total

1.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

Review 2.  Influence of transcriptional variants on metastasis.

Authors:  Joice De Faria Poloni; Diego Bonatto
Journal:  RNA Biol       Date:  2018-07-24       Impact factor: 4.652

3.  Aberrant expression of ETS1 and ETS2 proteins in cancer.

Authors:  Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Rep Rev       Date:  2018-04-23

4.  Pre-mRNA Splicing Modulation by Antisense Oligonucleotides.

Authors:  Natalia N Singh; Diou Luo; Ravindra N Singh
Journal:  Methods Mol Biol       Date:  2018

Review 5.  p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Concept.

Authors:  Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2016-11-10       Impact factor: 5.923

Review 6.  Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.

Authors:  Jung-Chun Lin
Journal:  Int J Mol Sci       Date:  2017-12-28       Impact factor: 5.923

Review 7.  The Role of Alternative RNA Splicing in the Regulation of hTERT, Telomerase, and Telomeres: Implications for Cancer Therapeutics.

Authors:  Aaron L Slusher; Jeongjin Jj Kim; Andrew T Ludlow
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.